Overall, at 6 months, the risk of the composite vascular endpoint (vascular death, myocardial infarction, or stroke) did not differ between treatment groups ( p = 0.52), while analysis of functional outcome (shift in modified Rankin Scale (mRS) using ordinal logistic regression) suggested a nominally significant ( p = 0.048) higher risk of poor outcome in the candesartan group (not significant after multiple testing correction at p ≤ 0.025).
76 Dependency, early neurological deterioration and death In the CATIS trial, 72 a secondary subgroup analysis for the primary outcome (combination of death and major disability (mRS 3–6) at 14 days or hospital discharge) showed a trend ( p = 0.06) towards interaction with ischaemic stroke subtypes.
In the SCAST trial, 73 there was a significant trend towards a better functional outcome (mRS, ordinal logistic regression) with candesartan in patients with total anterior circulation ischaemic stroke (TACI) and partial anterior circulation ischaemic stroke (PACI), than in patients with lacunar infarction (LACI, p value for trend = 0.02). 82 The difference was no longer significant in the adjusted analysis, and, overall, there was no heterogeneity of treatment effect between the subgroups ( p = 0.11) 82 ( Supplemental Table 6 ).